GSK-3β inhibitor 17_product_DataBase

Bioactivity	GSK-3β inhibitor 17 (compound 5 n) is a potent GSK-3β inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury[1].
Invitro	GSK-3β inhibitor 17 (compound 5 n) (16, 32, 64 µM) 以剂量依赖性方式降低顺铂 (HY-17394) 诱导的 p-p65、KIM-1 蛋白表达[1]。GSK-3β inhibitor 17 (32 µM) 降低顺铂诱导的 HK-2 细胞急性肾损伤 (AKI) 模型中的 TNF-α、IL-1β、IL-6 和 MCP-1 mRNA 表达水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> GSK-3β inhibitor 17 相关抗体: Western Blot Analysis[1] Cell Line:
In Vivo	GSK-3β inhibitor 17 (12.5, 25, 50 mg/kg; i.p.) 可降低顺铂 (HY-17394) 诱导的 NF-κB 信号激活和炎症细胞因子释放，从而减轻肾损伤[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2521624-67-7
Formula	C26H18F3N5O6S2
Molar Mass	617.58
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Cai YT, et al. A novel GSK3β inhibitor 5n attenuates acute kidney injury. Heliyon. 2024 Apr 12;10(8):e29159.

PeptideDB